肺炎支原体及其人用疫苗研究进展  

Research Progress of Mycoplasma pneumoniae and its Vaccine for Human

作　　者：梁宇(综述) 廖国阳(审校)[1] LIANG Yu;LIAO Guo-Yang(Institute of Medical Biology,Chinese Academy of Medical Sciences and Peking Union Medical College,Kunming 650031,China)

机构地区：[1]中国医学科学院北京协和医学院医学生物学研究所,云南昆明650031

出　　处：《生物技术通讯》2020年第2期190-195,共6页Letters in Biotechnology

基　　金：中国医学科学院医学与健康科技创新工程(2016-I2M-3-026);云南省创新团队项目(2015HC027);云南省应用基础研究计划(2017FB039)。

摘　　要：肺炎支原体是老年人慢性阻塞性肺炎和儿童社区获得性肺炎的重要病原体,近几年引起的难治性和重症肺炎支原体肺炎有增多趋势,对儿童和老年人健康危害严重。疫苗是预防肺炎支原体肺炎的最有效手段,但全球尚无人用肺炎支原体疫苗研制成功,而兽用肺炎支原体减毒活疫苗和灭活疫苗在国内外都已上市。因此,对肺炎支原体的相关致病机制及人用肺炎支原体疫苗的研究逐渐成为热点,通过对肺炎支原体致病机制的深入探索可对人用肺炎支原体疫苗的研发提供重要启示。Mycoplasma pneumoniae(Mp) is an important pathogen of chronic obstructive pulmonary disease in the elderly and community acquired pneumonia in children. In recent years, Mp causes more and more refractory and severe Mp pneumonia, which is harmful to the health of children and the elderly. Vaccine is the most effective way to prevent Mp pneumonia, but no Mp vaccine has been successfully developed in the world, whereas live attenuated and inactivated Mp vaccine for animal have come into the market at home and abroad. Therefore, the research on the pathogenesis of Mp and Mp vaccine for human has become a hot topic. The further exploration of the pathogenesis of Mp can provide important enlightenment for the research and development of Mp vaccine for human.

关 键 词：肺炎支原体 致病机制 疫苗 

分 类 号：R392.1[医药卫生—免疫学]